Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Marc, Gotkine ^a   Leah, Rozenstein ^a   Ofira, Einstein ^a   Oded, Abramsky ^a   Zohar, Argov ^a   Hanna, Rosenmann ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ANTISENSE OLIGONUCLEOTIDE; MEN 101; NEOSTIGMINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; ENZYME REGULATION; MOTONEURON; MOUSE; NONHUMAN; SURVIVAL RATE; ANIMAL; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; PATHOLOGY; TRANSGENIC MOUSE;

ACETYLCHOLINESTERASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; NEOSTIGMINE; OLIGONUCLEOTIDES, ANTISENSE; SUPEROXIDE DISMUTASE;

EID: 84896084932     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/845345     Document Type: Article

References (23)

1. Rao S. D., Weiss J. H., Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends in Neurosciences 2004 27 1 17 23 2-s2.0-0346156083 10.1016/j.tins.2003.11.001 (Pubitemid 38036974)
2. Rothstein J. D., Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Advances in Neurology 1995 68 7 27 2-s2.0-0029441620
3. Andres C., Beeri R., Friedman A., Lev-Lehman E., Henis S., Timberg R., Shani M., Soreq H., Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin I β gene expression followed by late-onset neuromotor deterioration. Proceedings of the National Academy of Sciences of the United States of America 1997 94 15 8173 8178 2-s2.0-0030873431 10.1073/pnas.94.15.8173 (Pubitemid 27343796)
4. Rodríguez-Ithurralde D., Maruri A., Rodríguez X., Motor neurone acetylcholinesterase release precedes neurotoxicity caused by systemic administration of excitatory amino acids and strychnine. Journal of the Neurological Sciences 1998 160 1 S80 S86 2-s2.0-0344542055 10.1016/S0022- 510X(98)00204-4 (Pubitemid 28522524)
5. Park S. E., Kim N. D., Yoo Y. H., Acetylcholinesterase plays a pivotal role in apoptosome formation. Cancer Research 2004 64 24 2652 2655 2-s2.0-10844242207 (Pubitemid 38500595)
6. Festoff B. W., Release of acetylcholinesterase in amyotrophic lateral sclerosis. Advances in Neurology 1982 36 503 517 2-s2.0-0020350258
7. Sindhuphak R., Karlsson E., Conradi S., Ronnevi L.-O., Immunoglobulins from patients with amyotrophic lateral sclerosis affect human erythrocyte acetylcholinesterase. Journal of the Neurological Sciences 1988 86 2-3 195 202 2-s2.0-0023686324
8. Halliday A. C., Greenfield S. A., From protein to peptides: a spectrum of non-hydrolytic functions of acetylcholinesterase. Protein and Peptide Letters 2012 19 2 165 172 2-s2.0-84858846990 10.2174/092986612799080149
9. Greenfield S. A., Zimmermann M., Bond C. E., Non-hydrolytic functions of acetylcholinesterase: the significance of C-terminal peptides. FEBS Journal 2008 275 4 604 611 2-s2.0-38549159882 10.1111/j.1742-4658.2007.06235.x (Pubitemid 351160966)
10. Brenner T., Hamra-Amitay Y., Evron T., Boneva N., Seidman S., Soreq H., The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB Journal 2003 17 2 214 222 2-s2.0-0037308205 10.1096/fj.02-0609com (Pubitemid 36164391)
11. Gurney M. E., Pu H., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., Caliendo J., Hentati A., Kwon Y. W., Deng H.-X., Chen W., Zhai P., Sufit R. L., Siddique T., Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994 264 5166 1772 1775 2-s2.0-0028284779 (Pubitemid 24227760)
12. Drachman D. B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J. D., Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Annals of Neurology 2002 52 6 771 778 2-s2.0-0036895241 10.1002/ana.10374 (Pubitemid 35403187)
13. Andres C., Seidman S., Beeri R., Timberg R., Soreq H., Transgenic acetylcholinesterase induces enlargement of murine neuromuscular junctions but leaves spinal cord synapses intact. Neurochemistry International 1998 32 5-6 449 456 2-s2.0-0032077169 10.1016/S0197-0186(97)00121-6 (Pubitemid 28287198)
14. Soreq H., Seidman S., Acetylcholinesterase-new roles for an old actor. Nature Reviews Neuroscience 2001 2 4 294 302 2-s2.0-0035320772 10.1038/35067589 (Pubitemid 33673070)
15. Rodríguez-Ithurralde D., Olivera S., Vincent O., Maruri A., In vivo and in vitro studies of glycine- and glutamate-evoked acetylcholinesterase release from spinal motor neurones: implications for amyotrophic lateral sclerosis/motor neurone disease pathogenesis. Journal of the Neurological Sciences 1997 152 1 S54 S61 2-s2.0-0343487605 10.1016/S0022-510X(97)00245-1 (Pubitemid 27505291)
16. Greenfield S., Vaux D. J., Parkinson's disease, Alzheimer's disease and motor neurone disease: identifying a common mechanism. Neuroscience 2002 113 3 485 492 2-s2.0-0037008862 10.1016/S0306-4522(02)00194-X (Pubitemid 34874673)
17. Aquilonius S.-M., Askmark H., Eckernas S.-A., Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine. Acta Neurologica Scandinavica 1986 73 6 628 632 2-s2.0-0022491862 (Pubitemid 16057834)
18. Akinci S. B., Ulu N., Yondem O. Z., Firat P., Guc M. O., Kanbak M., Aypar U., Effect of neostigmine on organ injury in murine endotoxemia: missing facts about the cholinergic antiinflammatory pathway. World Journal of Surgery 2005 29 11 1483 1489 2-s2.0-28244452587 10.1007/s00268-005-0073-2 (Pubitemid 41712686)
19. Anselmet A., Mayat E., Wietek S., Layer P. G., Payrastre B., Massoulié J., Non-antisense cellular responses to oligonucleotides. FEBS Letters 2002 510 3 175 180 2-s2.0-0037116599 10.1016/S0014-5793(01)03248-3 (Pubitemid 34093820)
20. Gilboa-Geffen A., Wolf Y., Hanin G., Melamed-Book N., Pick M., Bennett E. R., Greenberg D. S., Lester S., Rischmueller M., Soreq H., Activation of the alternative NF B pathway improves disease symptoms in a model of Sjogren's syndrome. PLoS ONE 2011 6 12 2-s2.0-83055198367 10.1371/journal.pone.0028727 e28727
21. Zimmerman G., Shaltiel G., Barbash S., Cohen J., Gasho C. J., Shenhar-Tsarfaty S., Shalev H., Berliner S. A., Shelef I., Shoham S., Friedman A., Cohen H., Soreq H., Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NF B pathway. Translational Psychiatry 2012 2, article e78 2-s2.0-84857167112 10.1038/tp.2012.4
22. Swarup V., Phaneuf D., Dupré N., Petri S., Strong M., Kriz J., Julien J.-P., Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor B-mediated pathogenic pathways. Journal of Experimental Medicine 2011 208 12 2429 2447 2-s2.0-84855515796 10.1084/jem.20111313
23. Evron T., Moyal-Segal L. B., Lamm N., Geffen A., Soreq H., RNA-targeted suppression of stress-induced allostasis in primate spinal cord neurons. Neurodegenerative Diseases 2005 2 1 16 27 2-s2.0-23844441866 10.1159/000086427 (Pubitemid 41158936)